CN110731970A - cell preparation for treating allergic rhinitis - Google Patents
cell preparation for treating allergic rhinitis Download PDFInfo
- Publication number
- CN110731970A CN110731970A CN201810796885.9A CN201810796885A CN110731970A CN 110731970 A CN110731970 A CN 110731970A CN 201810796885 A CN201810796885 A CN 201810796885A CN 110731970 A CN110731970 A CN 110731970A
- Authority
- CN
- China
- Prior art keywords
- cells
- umbilical cord
- mesenchymal stem
- stem cells
- collecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses cell preparations for treating allergic rhinitis, which firstly protect the application of mesenchymal stem cells in preparing a medicament for treating the allergic rhinitis and also protect a preparation method of cell preparations.
Description
Technical Field
The invention relates to cell preparations for treating allergic rhinitis, which are human umbilical cord Volton mesenchymal stem cell preparations, and a preparation method and application thereof.
Background
Allergic Rhinitis (AR), also known as allergic rhinitis, is a common disease of the ear, nose, throat and respiratory tract, and is an allergic disease of the nasal mucosa, which is mainly characterized by itching, sneezing, overflowing and clear nasal discharge and swelling of the nasal mucosa. the prevalence rate of allergic rhinitis is 10% -40%, wherein pollen allergy is commonly seen in Europe and North America, and perennial allergic rhinitis is commonly seen in Asia. although allergic rhinitis is not fatal, the learning and work of patients are affected due to significant discomfort of the nose and the whole body of patients, and if not treated correctly, about 30% of patients develop bronchial asthma, even pulmonary heart disease and other diseases seriously affecting the physical health and the quality of life of patients.
①, AR is an IgE-mediated allergic inflammatory reaction occurring in the nasal cavity, and is a biochemical and cellular cascade reaction caused by the allergen in allergic constitutional individuals, wherein the reaction is caused by the interaction between infiltrated inflammatory cells and normal cells ② family inheritance, AR patients are reported to be mostly specific allergic constitutions, allergic rhinitis patients with family other allergic disease history account for about 60%, the probability of the disease occurring in children of parents and children if both parents and children have AR offspring is 75% -100%, ③ is related to asthma, AR and asthma belong to respiratory tract chronic allergic diseases occurring in different parts, and 40% of allergic rhinitis patients can develop into asthma if effective treatment is not achieved.
Allergic rhinitis is an allergic inflammatory reaction mainly caused by immune reaction of nasal mucosa, which is mediated by IgE under the action of in vitro environmental factors.
Disclosure of Invention
The invention aims to provide cell preparations for treating allergic rhinitis.
The invention firstly protects the application of the mesenchymal stem cells in preparing the medicament for treating allergic rhinitis.
The mesenchymal stem cells are umbilical cord mesenchymal stem cells. The umbilical cord mesenchymal stem cells are prepared by taking umbilical cord Wolton area tissue blocks as raw materials. The umbilical cord Wolton tissue block is used as a raw material to prepare the umbilical cord mesenchymal stem cells, and a low serum culture medium is adopted in the process. The umbilical cord is an in vitro umbilical cord. The umbilical cord mesenchymal stem cells can be primary umbilical cord mesenchymal stem cells and also can be umbilical cord mesenchymal stem cells after passage. The umbilical cord mesenchymal stem cells after passage can be umbilical cord mesenchymal stem cells within 20 passages, specifically umbilical cord mesenchymal stem cells within 10 passages, and more specifically umbilical cord mesenchymal stem cells within 3-5 passages.
The invention also provides a preparation method of the cell preparations, which comprises the following steps of preparing umbilical cord mesenchymal stem cells by taking the umbilical cord Wolton area tissue blocks as raw materials to obtain the cell preparation, wherein a low-serum culture medium is adopted in the preparation process.
The umbilical cord mesenchymal stem cells can be primary umbilical cord mesenchymal stem cells and also can be umbilical cord mesenchymal stem cells after passage.
The preparation method of the primary umbilical cord mesenchymal stem cells sequentially comprises the following steps:
(1) culturing the umbilical cord Wolton area tissue block by adopting a low-serum culture medium until cells climb out;
(2) culturing the cells by adopting a low serum culture medium;
(3) collecting cells, digesting with pancreatin, and collecting the cells, namely the primary umbilical cord mesenchymal cells.
The umbilical cord mesenchymal stem cells after passage can be umbilical cord mesenchymal stem cells within 20 passages, specifically umbilical cord mesenchymal stem cells within 10 passages, and more specifically umbilical cord mesenchymal stem cells within 3-5 passages.
The passage method specifically comprises the following steps: umbilical cord mesenchymal cells 1: and 2, passage, adopting a low serum culture medium to culture cells, collecting the cells, digesting the cells by pancreatin, and collecting the cells.
The invention also provides a preparation method of the cell preparations, which comprises the following steps:
(1) culturing isolated umbilical cord Wolton zone tissue blocks by adopting a low-serum culture medium for 7-10 days;
(2) after the step (1) is completed, removing tissue blocks, and culturing cells by adopting a low serum culture medium to reach 80% confluency;
(3) after the step (2) is finished, collecting cells, digesting the cells by pancreatin, and collecting the cells, namely the P0 generation umbilical cord mesenchymal cells;
(4) generation of P0 umbilical cord mesenchymal cell 1: 2, passage, and culturing by adopting a low serum culture medium to reach 80% confluence;
(5) after the step (4) is finished, collecting cells, digesting the cells by pancreatin, and collecting the cells, namely the P1 generation umbilical cord mesenchymal cells;
(6) generation of P1 umbilical cord mesenchymal cell 1: 2, passage, and culturing by adopting a low serum culture medium to reach 80% confluence;
(7) after the step (6) is finished, collecting cells, digesting the cells by pancreatin, and collecting the cells, namely the P2 generation umbilical cord mesenchymal cells;
(8) generation of P2 umbilical cord mesenchymal cell 1: 2, passage, and culturing by adopting a low serum culture medium to reach 80% confluence;
(9) and (5) after the step (8) is finished, collecting cells, digesting by pancreatin, and collecting the cells to obtain the cell preparation.
The cell preparation prepared by any of the methods above also belongs to the protection scope of the invention.
The cell preparation of any is a cell preparation positive to CD126, the positive rate of CD126 is more than 95%, preferably more than 99%, the cell preparation of any is a cell preparation with the positive rates of CD29, CD44, CD90 and CD105 being more than 90%, the positive rates of CD29, CD44, CD90 and CD105 being preferably more than 95%, and further being preferably more than 99%, the positive rates of CD31 and CD34 of the cell preparation of any being less than 10%, preferably less than 7%, the positive rates of CD45 and HLA-DR of the cell preparation of any being less than 5%, preferably less than 3%, and further being preferably less than 1%, the positive rates of CD44, CD90 and CD105 being surface mesenchymal markers for identifying mesenchymal stem cells, the positive rates of CD29, CD29 and CD 36105 being high purity indicating that the cell preparation is mesenchymal stem cells and the CD29, a high purity index indicating that the CD29, a high purity index of the CD-29, a CD-29 and a HLA-29, a marker for transplanting index for transplanting a low HLA-29, and a CD-29-related marker for transplanting a CD-related marker for transplanting the three cell preparation for transplanting a.
The invention also protects the application of the cell preparation in preparing a medicament for treating allergic rhinitis.
The invention also protects medicines for treating allergic rhinitis, and the active ingredient of the medicines is mesenchymal cells.
The mesenchymal stem cells are umbilical cord mesenchymal stem cells. The umbilical cord mesenchymal stem cells are prepared by taking umbilical cord Wolton area tissue blocks as raw materials. The umbilical cord Wolton tissue block is used as a raw material to prepare the umbilical cord mesenchymal stem cells, and a low serum culture medium is adopted in the process. The umbilical cord is an in vitro umbilical cord. The umbilical cord mesenchymal stem cells can be primary umbilical cord mesenchymal stem cells and also can be umbilical cord mesenchymal stem cells after passage. The umbilical cord mesenchymal stem cells after passage can be umbilical cord mesenchymal stem cells within 20 passages, specifically umbilical cord mesenchymal stem cells within 10 passages, and more specifically umbilical cord mesenchymal stem cells within 3-5 passages.
The invention also protects medicines for treating allergic rhinitis, and the active ingredients of the medicines are the cell preparation.
The low serum culture medium of any above is a cell culture medium containing 3-5% (by volume) serum.
The low serum medium described in any of above comprises human epithelial growth factor 10ng/ml, human basic fibroblast growth factor 10ng/ml, recombinant human insulin-like growth factor 5. mu.g/ml, platelet-derived factor 10ng/ml, heparin 5. mu.g/ml, hydrocortisone 1. mu.g/ml, ascorbic acid 10. mu.g/ml, non-essential amino acid solution 1% (volume percent), L-glutamine 2mmol/L, fetal calf serum 3-5% (volume percent), penicillin 50U/ml, streptomycin 50. mu.g/ml, and the balance DMEM high glucose medium.
The non-essential amino Acid solution contained 10.0mM of Glycine, 10.0mM of L-Alanine, 10.0mM of L-Asparagine, 10.0mM of L-Aspartic Acid, 10.0mM of L-Glutamic Acid, 10.0mM of L-Proline and 10.0mM of L-Serine.
In the aspect of mesenchymal stem cell culture, 10 percent (volume percent) of fetal bovine serum is generally used, the serum concentration is as high as 20 percent (volume percent), the serum contains various plasma proteins, polypeptides, carbohydrates, growth factors, hormones and the like, the serum components are complex, and the difference between each batch of serum cannot ensure , in addition, although the serum contains a plurality of components beneficial to cell growth, components harmful to cells, such as complement, antibodies, endotoxin and the like, are inevitably contained, therefore, the cells cultured by the high-concentration serum are not suitable for clinical application, and the risk of clinical allergy is increased.
Mesenchymal cells commonly used for immunotherapy include bone marrow mesenchymal stem cells, umbilical cord mesenchymal stem cells, adipose-derived mesenchymal stem cells, umbilical cord blood mesenchymal stem cells, and the like. Compared with the common Mesenchymal Stem Cells (MSCs), the mesenchymal stem cells in the umbilical cord Wton interval have the advantages of abundant sources, no influence on donors, easy collection and transportation, low carcinogenic possibility, low virus pollution probability, weak immunogenicity, no social, ethical and legal disputes and the like. More importantly, the mesenchymal stem cells separated from the umbilical cord Wolton region have high content, higher proliferation capacity than bone marrow MSCs and lower immunogenicity than the bone marrow MSCs.
The cellular therapy is to regulate the immune balance of the patient from the perspective of cellular and humoral immunity by directly affecting the immune system of the patient, thereby achieving the goal of controlling allergic symptoms. The cell preparation provided by the invention is suitable for cell therapy of allergic rhinitis. The invention has great application value for treating allergic rhinitis.
Drawings
Fig. 1 is the results of markers (CD29, CD44, CD90, CD105, and CD126) for mesenchymal stem cells.
FIG. 2 shows the results of hematopoietic stem cell and endothelial cell markers (CD31, CD45, and CD 34).
FIG. 3 shows the results of the transplantation rejection-associated marker (HLA-DR).
FIG. 4 shows the results of phenotypic observations.
Fig. 5 shows the results of the pathological examination of the nasal mucosa.
FIG. 6 shows the results of IFN-. gamma.detection, IL-4 detection, IL-17 detection, and TNF- α detection.
FIG. 7 shows the results of IgE and histamine detection.
Detailed Description
The following examples are given to facilitate a better understanding of the invention, but do not limit the invention. The experimental procedures in the following examples are conventional unless otherwise specified. The test materials used in the following examples were purchased from a conventional biochemical reagent store unless otherwise specified. The quantitative tests in the following examples, all set up three replicates and the results averaged.
Low serum medium: 10ng/ml of human epithelial growth factor, 10ng/ml of human basic fibroblast growth factor, 5 mu g/ml of recombinant human insulin-like growth factor, 10ng/ml of platelet-derived factor, 5 mu g/ml of heparin, 1 mu g/ml of hydrocortisone, 10 mu g/ml of ascorbic acid, 1% (volume percent) of non-essential amino acid solution, 2mmol/L of L-glutamine, 4% (volume percent) of fetal bovine serum, 50U/ml of penicillin, 50 mu g/ml of streptomycin and the balance of DMEM high-sugar medium.
Human epithelial growth factor (hEGF): GenScript, EGF Recombinant human protein, Cat.Z 00333.
Human basic fibroblast growth factor (b-FGF): GenScript, Inc., cat # Z03116.
Recombinant human insulin-like growth factor (IGF): GenScript, Cat number Z03017.
Platelet derived factor (PDGF): GenScript, Inc., cat # Z02529.
Egg protein: sigma, cat # S7951.
Heparin: michael corporation. Hydrocortisone: michael corporation. Ascorbic acid: michael corporation. Penicillin: gibco Corp. Streptomycin: gibco Corp.
The non-essential amino acid solution is GibcoTMMEM Non-Essential Amino Acids Solution, (100X), cat # 11140050. The website address https:// www.thermofisher.com/cn/zh/home/technical-resources/media-formulation.165. html. The product contains seven amino acids, and comprises the following components: 10.0mM of Glycine, 10.0mM of L-Alanine, 10.0mM of L-Asparagine, 10.0mM of L-Aspartic acid, 10.0mM of L-Glutamine, 10.0mM of L-Proline and 10.0mM of L-Serine.
SD rat: beijing Wintonlihua, Inc.
Example 1 preparation of umbilical cord Wolton mesenchymal Stem cell preparation
obtaining umbilical cord of fetus
Taking the isolated umbilical cord of a full-term newborn without congenital diseases; the parturient has no infectious diseases such as hepatitis, syphilis, AIDS and the like, and the parturient and family members have informed consent to the experiment research of the umbilical cord.
Acquisition of mesenchymal cells in umbilical cord Wolton interval
1. In a sterile laboratory bench, the umbilical cord is repeatedly washed by normal saline, and residual blood is washed away. Cutting umbilical cord into 2-3cm segments with sterile surgical instrument, longitudinally cutting open umbilical cord, removing umbilical artery, umbilical vein and amnion, taking Wolton region, and cutting into 0.5-1mm segments3The left and right small blocks.
2. And (3) obtaining the primary umbilical cord mesenchymal cells by adopting a tissue mass culture method.
The method comprises the following specific steps:
(1) uniformly paving the Wolton area tissue blocks obtained in the step (1) in a sterile culture dish with the diameter of 10cm, covering 60-70% of the area of the dish bottom, and inversely placing the culture dish in an incubator at 37 ℃ for 15 min; the plate was inverted and 10ml of low serum medium was added gently at 37 ℃ with 5% CO2The culture box is cultured for 7-10 days, and the cells are evenly climbed out under the tissue block.
(2) And (3) taking the culture dish in the step (1), washing the culture dish for 2 times by using PBS buffer solution, removing tissue blocks (the cells grow adherent to the wall at the moment), adding 10ml of fresh low-serum culture medium into each dish (changing the solution for times in 3-4 days), and culturing until the cells are approximately 80% of the bottom of the culture dish.
(3) And (3) after the step (2) is finished, collecting cells, digesting the cells for 1 to 2min by using 0.25 percent pancreatin, centrifuging the cells for 3min at 1000rpm, and collecting the cells, namely the primary umbilical cord mesenchymal cells, which are also called P0 generation umbilical cord mesenchymal cells.
3. Obtaining P3 generation umbilical cord mesenchymal cells
(1) The P0 umbilical cord mesenchymal cells obtained in the step 2 are averagely divided into two sterile culture dishes with the diameter of 10cm (passage 1: 2), 10ml of fresh low-serum culture medium is respectively added into each culture dish (liquid is changed for times in 3-4 days), and the culture is carried out until the cells are approximately 80% of the bottom of the culture dish.
(2) And (3) after the step (1) is finished, collecting cells, digesting the cells for 1 to 2min by using 0.25 percent of pancreatin, centrifuging the cells for 3min at 1000rpm, and collecting the cells, namely the P1 generation umbilical cord mesenchymal cells.
(3) Averagely distributing the P1 umbilical cord mesenchymal cells obtained in the step (2) into sterile culture dishes with the diameter of 10cm (passage 1: 2), adding 10ml of fresh low-serum culture medium into each culture dish respectively (changing liquid times in 3-4 days), and culturing until the cells are approximately 80% of the bottom of the culture dish.
(4) And (4) after the step (3) is finished, collecting cells, digesting the cells for 1-2min by using 0.25% pancreatin, centrifuging for 3min at 1000rpm, and collecting the cells, namely the P2 generation umbilical cord mesenchymal cells.
(5) And (3) averagely dividing the P2 umbilical cord mesenchymal cells obtained in the step (4) into sterile culture dishes with the diameter of 10cm (passage 1: 2), adding 10ml of fresh low-serum culture medium into each culture dish respectively (liquid changing for times in 3-4 days), and culturing until the cells are fully paved at about 80% of the bottom of the culture dish.
(6) And (3) after the step (5) is finished, collecting cells, digesting the cells for 1-2min by using 0.25% pancreatin, centrifuging for 3min at 1000rpm, and collecting the cells, namely the P3 generation umbilical cord mesenchymal cells (also called P3 cell preparation).
Example 2 identification of P3 cell preparation
The test article was the P3 cell preparation prepared in example 1.
Detecting the expression of CD29, CD44, CD90, CD105, CD126, CD31, CD45, CD34 and HLA-DR in a test sample by flow cytometry, which comprises the following steps: after the cells are respectively incubated with corresponding antibodies, redundant antibodies are washed away, the cells are resuspended by PBS buffer solution, and the positive rate of each index is detected by using an LSR Fortessa instrument of BD company.
The results of markers for mesenchymal stem cells (CD29, CD44, CD90, CD105 and CD126) are shown in fig. 1. The results for hematopoietic stem cell and endothelial cell markers (CD31, CD45, and CD34) are shown in fig. 2. The results of the marker associated with transplant rejection (HLA-DR) are shown in FIG. 3. The results show that the sample highly expresses the markers of the mesenchymal stem cells (the positive rate is more than 95 percent), lowly expresses the markers of the hematopoietic stem cells and the endothelial cells (the positive rate is less than 10 percent), and does not basically express the markers related to the transplant rejection (only 0.2 percent).
Example 3 therapeutic Effect of P3 cell preparation on allergic rhinitis
Antigen adjuvant suspension: egg protein 1mg/ml, aluminium hydroxide 2mg/ml, balance normal saline.
Egg protein solution: egg albumen 0.1mg/ml, balance normal saline.
preparation model and administration
Adopting gel containing egg protein and aluminium hydroxide to carry out allergic rhinitis induction model on rats.
SD rats, half male and female, weighing about 250g, were acclimatized for weeks (clean animal housing, free access to food water) and then treated in groups of 12 rats per group as follows:
cell treatment group, on test day 1, antigen adjuvant suspension was injected ( point per hind limb metatarsal and three points in the abdominal cavity, total injection of 5 points, each point being 0.2ml), on test day 7, antigen adjuvant suspension was injected ( point per hind limb metatarsal and three points in the abdominal cavity, total injection of 5 points, each point being 0.2ml), on test days 14 to 27, egg protein solution was dropped once per day (both nostrils were dropped at 50. mu.l per side), on test days 14, 21, 28, and 35, P3 cell preparation prepared in example 1 was injected intraperitoneally times (each 5X 10 cells each time)6Individual cells);
model group, injecting antigen adjuvant suspension ( points of each hind limb metatarsal part and three points of abdominal cavity, total injection of 5 points and 0.2ml of each point) on the test day 1, injecting antigen adjuvant suspension ( points of each hind limb metatarsal part and three points of abdominal cavity, total injection of 5 points and 0.2ml of each point) on the test day 7, and dripping a nasal -time egg protein solution (both nostrils on both sides drop and each side drop by 50 mul) every day on the test days 14 to 27;
normal control group, injection of normal saline ( points per hind foot, three points in abdominal cavity, total injection of 5 points, each point being 0.2ml) on test day 1, injection of sterile normal saline ( points per hind foot, three points in abdominal cavity, total injection of 5 points, each point being 0.2ml) on test day 7, and nasal drops of normal saline (both nostrils drop, 50 μ l on each side) per day from test day 14 to 27.
Second, phenotypic observations
On day 36 of the experiment, rats in the cell treatment group and the model group were nose-dropped with an egg protein solution (both nostrils were dropped with 50. mu.l each side), rats in the normal control group were nose-dropped with a physiological saline solution (both nostrils were dropped with 50. mu.l each side), and after nose-dropping, each rat was placed in observation boxes and observed for 10 minutes, and the number of sneezing and nose-catching thereof were counted.
The results are shown in FIG. 4. Compared with the model group, the number of sneezing and nose grabbing times of the rats in the treatment group are obviously reduced, namely the cell preparation has obvious curative effect on allergic rhinitis.
Third, pathological detection of nasal mucosa
On day 36 of the experiment, nasal mucosa tissues of rats were taken, paraffin sections (section thickness 4 μm) were prepared, and hematoxylin-eosin staining was performed.
The results are shown in FIG. 5. In the normal control group, the mucous membrane tissues of rats have the defects that epithelial cells are regularly arranged, cilia are complete, a small amount of inflammatory cells gather under the basement membrane, and gland hyperplasia is not obvious. The mucosal tissues of the rats in the model group show that epithelial cells are disorderly arranged, cilia are lodged and lost, goblet cells in the epithelia are increased, a large amount of inflammatory cell infiltration such as lymphocytes and eosinophils can be seen under a basement membrane, and hyperplasia of glands and vasodilatation are obvious. In the treatment group rats, the proliferation of the glands is inhibited, i.e. the cell preparation protects the integrity of the mucosal tissue.
Fourth, blood biochemical and immunological index detection
On the 36 th day of the experiment, blood was taken from the abdominal aorta of rats, and serum was collected, and IFN-. gamma., IL-4, IL-17, TNF- α, IgE, and histamine levels in serum were detected.A kit for detecting IFN-. gamma.was a product of Union Bio Inc., having a product number of 70-EK3802, a kit for detecting IL-4 was a product of Union Bio Inc., having a product number of 70-EK3042, a kit for detecting IL-17 was a product of eBioscience Inc., having a product number of 85-88-7170-88, a kit for detecting TNF- α was a product of eBioscience Inc., having a product number of 85-88-7340-86, a kit for detecting IgE was a product of GenWayBiotech, Inc., having a product number of GWB-500760, and a kit for detecting histamine was a product of ADI, having a product number of 196030-15.
The detection results of IFN-gamma, IL-4, IL-17 and TNF- α are shown in figure 6, the detection results of IgE and histamine are shown in figure 7.
Claims (10)
1. Application of mesenchymal stem cells in preparing a medicament for treating allergic rhinitis.
2. The use of claim 1, wherein: the mesenchymal stem cells are umbilical cord mesenchymal stem cells.
3. Use according to claim 2, characterized in that: the umbilical cord mesenchymal stem cells are prepared by taking umbilical cord Wolton area tissue blocks as raw materials.
The preparation method of kinds of cell preparation includes the following steps, umbilical cord mesenchymal stem cells are prepared by using umbilical cord Wolton area tissue blocks as raw materials, and a low serum culture medium is adopted in the preparation process.
The preparation method of the cell preparation of kinds comprises the following steps:
(1) culturing isolated umbilical cord Wolton zone tissue blocks by adopting a low-serum culture medium for 7-10 days;
(2) after the step (1) is completed, removing tissue blocks, and culturing cells by adopting a low serum culture medium to reach 80% confluency;
(3) after the step (2) is finished, collecting cells, digesting the cells by pancreatin, and collecting the cells, namely the P0 generation umbilical cord mesenchymal cells;
(4) generation of P0 umbilical cord mesenchymal cell 1: 2, passage, and culturing by adopting a low serum culture medium to reach 80% confluence;
(5) after the step (4) is finished, collecting cells, digesting the cells by pancreatin, and collecting the cells, namely the P1 generation umbilical cord mesenchymal cells;
(6) generation of P1 umbilical cord mesenchymal cell 1: 2, passage, and culturing by adopting a low serum culture medium to reach 80% confluence;
(7) after the step (6) is finished, collecting cells, digesting the cells by pancreatin, and collecting the cells, namely the P2 generation umbilical cord mesenchymal cells;
(8) generation of P2 umbilical cord mesenchymal cell 1: 2, passage, and culturing by adopting a low serum culture medium to reach 80% confluence;
(9) and (5) after the step (8) is finished, collecting cells, digesting by pancreatin, and collecting the cells to obtain the cell preparation.
6. A cell preparation produced by the method of claim 4 or 5.
7. Use of a cell preparation according to claim 6 for the manufacture of a medicament for the treatment of allergic rhinitis.
8, A medicine for treating allergic rhinitis, wherein the active ingredient is mesenchymal stem cells.
9. The medicament of claim 8, wherein: the mesenchymal stem cells are umbilical cord mesenchymal stem cells.
10, A medicament for treating allergic rhinitis, which comprises the cell preparation according to claim 6 as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810796885.9A CN110731970A (en) | 2018-07-19 | 2018-07-19 | cell preparation for treating allergic rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810796885.9A CN110731970A (en) | 2018-07-19 | 2018-07-19 | cell preparation for treating allergic rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110731970A true CN110731970A (en) | 2020-01-31 |
Family
ID=69233859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810796885.9A Pending CN110731970A (en) | 2018-07-19 | 2018-07-19 | cell preparation for treating allergic rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110731970A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111202751A (en) * | 2018-11-21 | 2020-05-29 | 清华大学 | Application of mesenchymal stem cells in preparation of product for treating rheumatoid arthritis |
| CN111956667A (en) * | 2020-08-26 | 2020-11-20 | 北京达熙生物科技有限公司 | Application of multifunctional stem cell exosome and mesenchymal stem cell lysate in preparation of medicine for treating allergic rhinitis |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101525594A (en) * | 2009-04-17 | 2009-09-09 | 中国医学科学院血液学研究所 | Complete medium with low serum concentration for cultivating mesenchymal stem cells and method for cultivating mesenchymal stem cells using same |
| CN102827807A (en) * | 2012-09-19 | 2012-12-19 | 北京京蒙高科干细胞技术有限公司 | Serum-free culture medium for mesenchymal stem cells |
| CN102965338A (en) * | 2012-12-04 | 2013-03-13 | 东南大学 | Extraction and culture method of human umbilical cord mesenchymal stem cells |
| CN104673748A (en) * | 2015-03-19 | 2015-06-03 | 河南中科干细胞基因工程有限公司 | Method for extracting mesenchymal stem cells from human umbilical cord |
| CN107475184A (en) * | 2016-06-07 | 2017-12-15 | 广州美萨生物科技有限公司 | A kind of low blood serum medium for being used to cultivate human mesenchymal stem cell |
-
2018
- 2018-07-19 CN CN201810796885.9A patent/CN110731970A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101525594A (en) * | 2009-04-17 | 2009-09-09 | 中国医学科学院血液学研究所 | Complete medium with low serum concentration for cultivating mesenchymal stem cells and method for cultivating mesenchymal stem cells using same |
| CN102827807A (en) * | 2012-09-19 | 2012-12-19 | 北京京蒙高科干细胞技术有限公司 | Serum-free culture medium for mesenchymal stem cells |
| CN102965338A (en) * | 2012-12-04 | 2013-03-13 | 东南大学 | Extraction and culture method of human umbilical cord mesenchymal stem cells |
| CN104673748A (en) * | 2015-03-19 | 2015-06-03 | 河南中科干细胞基因工程有限公司 | Method for extracting mesenchymal stem cells from human umbilical cord |
| CN107475184A (en) * | 2016-06-07 | 2017-12-15 | 广州美萨生物科技有限公司 | A kind of low blood serum medium for being used to cultivate human mesenchymal stem cell |
Non-Patent Citations (4)
| Title |
|---|
| CHUNLEI LI等: "Mesenchymal stromal cells ameliorate acute allergic rhinitis in rats", 《CELL BIOCHEM FUNCT》 * |
| IZASKUN FERRIN等: "Isolation, Culture, and Expansion of Mesenchymal Stem Cells", 《STEM CELL BANKING 》 * |
| ZHONG‑BAO RUAN等: "Karyotype stability of human umbilical cord‑derived mesenchymal stem cells during in vitro culture", 《EXPERIMENTAL AND THERAPEUTIC MEDICINE》 * |
| 张菊芳主编: "《现代毛发移植技术》", 31 May 2018, 浙江科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111202751A (en) * | 2018-11-21 | 2020-05-29 | 清华大学 | Application of mesenchymal stem cells in preparation of product for treating rheumatoid arthritis |
| CN111956667A (en) * | 2020-08-26 | 2020-11-20 | 北京达熙生物科技有限公司 | Application of multifunctional stem cell exosome and mesenchymal stem cell lysate in preparation of medicine for treating allergic rhinitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Russell et al. | Modifiers of mesenchymal stem cell quantity and quality | |
| Ma et al. | Immunosuppressive effect of exosomes from mesenchymal stromal cells in defined medium on experimental colitis | |
| CN105861430A (en) | Exosome, preparing method of exosome and application of exosome in preparing medicine or preparation for treating sepsis | |
| CN108823156A (en) | For the clinical grade human umbilical cord mesenchymal stem cells composite factor of reparation and the preparation method of freeze-dried powder | |
| CN112121063B (en) | Application of exosome in preparation of medicine for treating pulmonary fibrosis | |
| WO2020103651A1 (en) | Use of mesenchymal stem cells in preparation of product for treating rheumatoid arthritis | |
| CN111979187B (en) | Method for resisting aging of human mesenchymal stem cells and enhancing dryness characteristics of human mesenchymal stem cells | |
| CN107385517A (en) | The construction method of mesenchyma stem cell | |
| CN110731970A (en) | cell preparation for treating allergic rhinitis | |
| CN116474000B (en) | Umbilical cord mesenchymal stem cell preparation, preparation method and application thereof in treating knee osteoarthritis | |
| KR102173640B1 (en) | Composition for preventing or treating inflammatory disease comprising induced pluripotent stem cell derived mesenchymal stem cell | |
| CN106606512B (en) | Mixed cell preparation for treating myocardial infarction and preparation method and application thereof | |
| CN106834217A (en) | A kind of method for promoting human amnion membrane amplification in vitro and application | |
| CN115125192B (en) | Bone marrow supernatant and application thereof in cell culture | |
| CN108451981B (en) | Use skin mesenchymal stem cells treatment system sclerosis | |
| CN115281184A (en) | Mesenchymal stem cell composite cryopreservation solution as well as preparation method and application thereof | |
| CN110205288B (en) | Cell preparation for treating inflammatory enteritis | |
| CN106676063A (en) | Separate culture method for human amniotic mesenchymal stem cells | |
| CN113652398A (en) | Method and compound for enhancing mucosa repair effect of mesenchymal stem cell exosome | |
| CN102119936A (en) | Method for preparing injection for treating ischemic brain damage by using human amniotic mesenchymal cells and injection | |
| CN111514164A (en) | Adipose-derived mesenchymal stem cells for treating lung diseases and preparation method thereof | |
| CN109536443A (en) | Mescenchymal stem cell, cell culture medium and cultural method and application | |
| CN117431208B (en) | Preparation and application of TRIM15 high-expression extracellular vesicles | |
| CN110885785B (en) | Method for separating and culturing mesenchymal stem cells | |
| RU2742034C2 (en) | Cell-free therapeutic agents for regenerative medicine and methods for preparing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200131 |